TG Therapeutics: A Biotech Stock to Watch in 2025

TG Therapeutics (NasdaqCM:TGTX) has been making waves in the biotech industry with its strong financial performance and optimistic earnings guidance for 2025. The company's stock price increased by 3.7% over the last week, coinciding with the announcement of robust fourth-quarter earnings results and a positive outlook for the coming year. This article will delve into the key factors driving TG Therapeutics' success and explore the implications for investors considering the company as a potential investment.



TG Therapeutics' impressive stock performance over the past three years has been influenced by several strategic decisions. In September 2024, the company was added to major indices, including the S&P 600 and S&P Composite 1500, boosting investor visibility and confidence. Additionally, TG Therapeutics announced an agreement with Neuraxpharm Group in August 2023 to expand BRIUMVI's commercialization outside the U.S., signaling international growth opportunities. In November 2024, the company completed a share buyback program, enhancing shareholder value. Clinical advancements, such as FDA clearance for a new multiple sclerosis treatment, azer-cel, in August 2024, further broadened the company's pipeline. These strategic moves, combined with the company's strong financial performance, have contributed to its substantial total return of 247.06% over the past three years.

TG Therapeutics' optimistic earnings guidance for 2025 is driven by several key factors that contribute to the company's long-term growth potential. The company's BRIUMVI product has shown remarkable growth in the U.S. market, with U.S. net product revenue reaching $310 million in 2024, representing approximately 250% growth year over year. The company expects BRIUMVI U.S. net product revenue to reach approximately $525 million in 2025, further solidifying its position as a key driver of the company's growth. International expansion, clinical advancements, shareholder value enhancement, and index inclusion have all contributed to TG Therapeutics' positive outlook.

Investors considering TG Therapeutics as a potential investment should take into account the company's strong relative performance compared to its peers in the biotech industry. The company's positive outlook, driven by its BRIUMVI product and other key developments, may indicate a promising investment opportunity. However, it is essential to conduct a thorough analysis of the company's fair value, potential risks, and other relevant factors before making an investment decision.

In conclusion, TG Therapeutics' strong financial performance and positive outlook make it a biotech stock to watch in 2025. The company's strategic decisions, such as index inclusion, international expansion, share buybacks, and clinical advancements, have contributed to its impressive stock performance over the past three years. Investors should carefully evaluate the company's potential as an investment opportunity, considering its strong relative performance and optimistic earnings guidance for the coming year.